BioCentury | Apr 17, 2021
Product Development

How COVID vaccines might be causing blood clots with low platelets

...injections.TARGETSPF4 (CXCL4) – Platelet factor 4tPATissue plasminogen activator Sandi...
BioCentury | Jan 29, 2021
Management Tracks

Kirk Raab, first BIO chair and early Genentech CEO, dies at 85

...its facility to manufacture tissue  plasminogen activator (tPA...
...change the name of the company to tPA...
...Bugos interview. “Tom, if we don’t have tPA...
BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

...in stroke but one that’s eluded development in any indication. Unlike SOC alteplase, a recombinant tissue plasminogen activator (tPA)...
...the interaction between nerinetide and tPA by giving the two drugs sequentially, first nerinetide, then tPA...
...ND2 - NADH dehydrogenase subunit 2 PSD95 (DLG4) - Discs large homolog 4 tPA - Tissue plasminogen activator...
BioCentury | Oct 11, 2019
Targets & Mechanisms

CAR Ts can move well beyond cancer, but will need to go allogeneic first

...He also proposed designing CAR T cells to dissolve blood clots by making them express TPA...
BioCentury | Oct 5, 2018
Company News

BARDA, Genentech partner against influenza, health security threats

...where Shionogi retains rights. The drug is approved as Xofluza in Japan. Alteplase is a tissue plasminogen activator...
BioCentury | Oct 4, 2018
Emerging Company Profile

Banking on exosomes

...from FDA. ALX-051 is in development for bleeding disorders with antiplasmin and antitissue plasminogen activator (tPA...
BioCentury | Oct 1, 2018
Company News

BARDA, Genentech partner against influenza, health security threats

...where Shionogi retains rights. The drug is approved as Xofluza in Japan. Alteplase is a tissue plasminogen activator...
...a unit of Roche (SIX:ROG; OTCQX:RHHBY). Alicia Parker Actilyse, Actilyse Cathflo, Activacin, Activase, Cathflo Activase, GRTPA, alteplase (Tissue plasminogen activator (tPA)) Xofluza...
BioCentury | Jul 24, 2018
Distillery Therapeutics

Neurology

...with either therapy alone. In a microembolic mouse model of ischemic stroke, the inhibitor plus tissue plasminogen activator (tPA)...
...either agent alone. Next steps could include testing the C3d deposition inhibitor in combination with tPA...
BioCentury | Feb 9, 2018
Clinical News

ZZ Biotech's 3K3A-APC reduces hemorrhage rate in Phase II for acute ischemic stroke

...in 110 patients with moderate to severe acute ischemic stroke who were treated with IV tissue plasminogen activator (tPA)...
BioCentury | Dec 10, 2016
Product Development

Rules of the road

...the answer is no. On Dec. 5, Rebecca Gardner presented data from the Phase I/II PLAT-02...
Items per page:
1 - 10 of 322